


















What is claimed:

























1. A compound of formula 1:




1















and/or a pharmaceutically acceptable salt thereof, which is selected from:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
















,

,

,




,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,


















,

,

,

,

,

,


,














,



,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,


,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

, and


.

2. A compound as claimed in claim 1 which is selected from:




and/or a pharmaceutically acceptable salt thereof.

3. A compound as claimed in claim 1 which is:



and/or a pharmaceutically acceptable salt thereof.

4. A compound of formula 1 as claimed in claim 1 which is:



.

5. A composition comprising a compound of any one of claims 1 to 3, and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

6. Use of a compound as claimed in any one of claims 1 to 3, and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer responsive to inhibition of c-Met.

7. Use of a compound as claimed in any one of claims 1 to 3, and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer responsive to inhibition of c-Met comprising a step of administering to the subject an amount of an additional anti-neoplastic agent, wherein said anti-neoplastic agent is different from said compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof.

8. Use of a compound as claimed in any one of claims 1 to 3, and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer responsive to inhibition of c-Met, wherein the medicament is administered in combination with Gefitinib.

9. Use of a compound as claimed in any one of claims 1 to 3, and/or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer responsive to inhibition of c-Met, wherein the medicament is administered in combination with Docetaxel.